ProQR Therapeutics NV
NASDAQ:PRQR

Watchlist Manager
ProQR Therapeutics NV Logo
ProQR Therapeutics NV
NASDAQ:PRQR
Watchlist
Price: 2.36 USD 5.83%
Market Cap: 248.3m USD

Wall Street
Price Targets

PRQR Price Targets Summary
ProQR Therapeutics NV

Wall Street analysts forecast PRQR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRQR is 9.82 USD with a low forecast of 5.05 USD and a high forecast of 14.7 USD.

Lowest
Price Target
5.05 USD
114% Upside
Average
Price Target
9.82 USD
316% Upside
Highest
Price Target
14.7 USD
523% Upside
ProQR Therapeutics NV Competitors:
Price Targets
BIOPOR
Bioporto A/S
281% Upside
ALT
Altimmune Inc
254% Upside
TVTX
Travere Therapeutics Inc
21% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
51% Upside
2171
CARsgen Therapeutics Holdings Ltd
48% Upside
688331
RemeGen Co Ltd
8% Upside
CYTK
Cytokinetics Inc
34% Upside
4974
Takara Bio Inc
42% Upside

Revenue
Forecast

Revenue Estimate
ProQR Therapeutics NV

For the last 11 years the compound annual growth rate for ProQR Therapeutics NV's revenue is 59%. The projected CAGR for the next 3 years is -20%.

59%
Past Growth
-20%
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Operating Income
Forecast

Operating Income Estimate
ProQR Therapeutics NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
9%
Average Beat

Net Income
Forecast

Net Income Estimate
ProQR Therapeutics NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-61%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PRQR's stock price target?
Price Target
9.82 USD

According to Wall Street analysts, the average 1-year price target for PRQR is 9.82 USD with a low forecast of 5.05 USD and a high forecast of 14.7 USD.

What is ProQR Therapeutics NV's Revenue forecast?
Projected CAGR
-20%

For the last 11 years the compound annual growth rate for ProQR Therapeutics NV's revenue is 59%. The projected CAGR for the next 3 years is -20%.

Back to Top